Skip to content
About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Posttraumatic Stress Disorder
Long COVID
Cocaine Intoxication
Migraine
Depression
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
Monkeypox
Smallpox
COVID-19
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-601 ER
TNX-1300
TNX-1900
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-801
TNX-1850
Rare Disease
TNX-2900
Scientific Presentations
Expanded Access Policy
Clinical Trials
News & Events
Tonix in the News
Press Releases
Investor Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Chronic Migraine and Major Depressive Disorder. Please visit
Clinical Trials
.
Scientific Presentations
April 2023
AACR: MDSC-targeted TFF2-MSA Synergizes with PD-1 Blockade Therapy in Advanced Gastric Cancer Models
April 2023
AACR: MDSC-Targeted mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in Anti-PD-1 Treated MC38 and CT26.wt Murine Colorectal Cancer Models
April 2023
TNX-801: A Novel Mpox Vaccine: Live, Replicating, Attenuated Orthopoxvirus (Horsepox) Vaccine
April 2023
The Development of Horsepox Virus as a Vaccine Platform: Evaluation of TNX-1800 as a SARS-CoV-2 Vaccine
March 2023
The 5th International Congress on Controversies in Fibromyalgia
March 2023
Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: Results from the Randomized, Placebo-Controlled RELIEF Trial
March 2023
TNX-2900 — Rare Disease Summit, Philadelphia, 23-March-2023
March 2023
mTFF2-MSA (mTNX-1700) Suppresses Tumor Growth and Increases Survival in an Anti-PD-1 Treated MC38 Colorectal Cancer Model by Targeting MDSCs
January 2023
Primary vs Secondary Sex Hormones and Migraine
January 2023
Targeting the Wnt/β-catenin pathway as a broad-spectrum antiviral strategy
December 2022
Live Virus Smallpox and Monkeypox Vaccine
November 2022
Platform for Generating Fully Human anti-SARS-CoV-2 Spike Therapeutic Monoclonal Antibodies
November 2022
In Vitro Impact of Oxytocin on Human Sensory Neurons
September 2022
Retrospective Observational Database Study of Patients with Long COVID with Multi-Site Pain, Fatigue, and Insomnia: A Real-World Analysis of Symptomatology and Opioid Use
September 2022
Monotherapy with TNX-1500, an Fc-modified Anti-CD154 mAb, Prolongs Cardiac Allograft Survival in Cynomolgus Monkeys
September 2022
Long-term (>1 year) Rejection/TMA Free Survival of Kidney Xenografts with Triple Xenoantigen Knockout and Multiple Human Transgenes in Nonhuman Primates
September 2022
Long-term Rejection Free Renal Allograft Survival with Fc-modified Anti-CD154 Antibody Monotherapy in Nonhuman Primates
June 2022
TNX-1500, an Fc-modified Anti-CD154 Antibody,
Prolongs Nonhuman Primate Cardiac Allograft Survival
June 2022
Long Term Rejection Free Renal Allograft Survival with Fc Modified Anti CD154 Antibody Monotherapy in Nonhuman Primates
June 2022
Novel Targetable Pathways in Costimulation Pathway Blockade
June 2022
The Virus-host Interface: A Treasure Trove of Novel Antiviral Targets
June 2022
Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox
November 2021
TNX-601 CR*: a Once-Daily Formulation of Tianeptine in Development for the Treatment of Major Depressive Disorder
November 2021
TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial
July 2020
Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)
June 2021
Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Trial
June 2021
Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on PTSD Sleep-Dependent Emotional Memory Processing: Retrospective Analysis of Phase 2 and 3 Trial Results in Military-Related and Civilian PTSD
June 2020
Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer
January 2020
Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox*
November 2019
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome
May 2019
Steady-State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX-102 SL*): Comparison to Simulations of Oral Immediate Release CBP
November 2018
Differential Treatment Effects of a Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) on Dissociative Symptoms of Derealization and Depersonalization in a Military-Related PTSD
November 2018
Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*,a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)
August 2017
Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Mediators and Moderators of Treatment Response
August 2017
Efficacy and Safety of a Low Dose, Bedtime, Proprietary, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL#) for the Treatment of Military-Related PTSD: Study Protocol of a Phase 3 Randomized Placebo-Controlled Trial (P301)
August 2018
Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies
May 2018
Including Suicidal Individuals in Treatment Trials: Treatment of Military-Related PTSD with TNX-102 SL, a Novel Sublingual Formulation of Cyclobenzaprine Hypothesized to Address PTSD through Improvement in Sleep Quality
June 2017
Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response
May 2017
Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response
May 2017
Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder (PTSD): Mediators and Moderators of Treatment Response
December 2016
The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX – 102 SL in the Treatment of Military-Related PTSD
November 2016
Low-Dose Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD: Results of a Phase 2 Randomized, Placebo-Controlled Multicenter Trial
November 2016
The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD
October 2016
A Retrospective Analysis of the Efficacy of TNX-102 SL in Military-Related PTSD: Determining the Appropriate Severity Threshold for Trial Entry Using the Clinician-Administered PTSD Scale for DSM-5
October 2016
Tonix PTSD Awareness Day – October 26, 2016: Dr. Gregory Sullivan – Results of the Phase 2 “AtEase Study” in Military-Related PTSD
October 2016
Tonix PTSD Awareness Day – October 26, 2016: Dr. Jonathan Davidson – A Review of Pharmacotherapy for PTSD
October 2016
Tonix PTSD Awareness Day – October 26, 2016: Dr. Thomas A. Mellman – Focus on Sleep and PTSD Treatment Populations
August 2016
The AtEase Study: Efficacy and Safety of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
June 2016
TNX-102 SL for the Treatment of Fibromyalgia — Comparison of 30% Pain Respondent Analysis with Omeract Draft Composite Responder Endpoint Analyses
June 2016
A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
May 2016
A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
March 2016
Rapid Sublingual Absorption of Cyclobenzaprine (CBP) with Basifying Agents: Prospect for Bedtime Treatment of Fibromyalgia Syndrome (FM) Presentation Number: LB-026
November 2015
Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)
November 2015
Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)
November 2015
Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
November 2015
An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD
November 2015
Comparative Neuropharmacology of Therapeutic Agents Targeting Posttraumatic Stress Disorder
June 2015
Serotonin Receptor Profiles of Bedtime Pharmacotherapies Targeting Posttraumatic Stress Disorder (PTSD)
June 2015
TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement
June 2015
TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization
August 2015
The (R)-isomer of isometheptene, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models
August 2015
The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD
August 2015
(R)-isometheptene* (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache
November 2013
Cyclobenzaprine (CBP) and its Major Metabolite Norcyclobenzaprine (nCBP) are Potent Antagonists of the Serotonin Receptor 2A, Histamine H1 and α-Adrenergic Receptors: Mechanistic and Safety Implications…
LOAD MORE
